CN Patent

CN105884900A — 单特异性和双特异性抗igf-1r和抗erbb3抗体

Assigned to Merrimack Pharmaceuticals Inc · Expires 2016-08-24 · 10y expired

What this patent protects

本文提供适用作抗赘生剂且特异性结合人IGF-IR和人ErbB3的新颖单特异性和双特异性抗体。示例性抗体抑制经由IGF-IR和ErbB3中的任一者或两者进行的信号转导。示例性多价蛋白质包含至少一个抗IGF-1R结合位点和至少一个抗ErbB3结合位点。在某些实施方案中，结合位点可经由免疫球蛋白恒定区连接。还提供新颖抗ErbB3和抗IGF-1R抗体(例如，单克隆抗体)。

USPTO Abstract

本文提供适用作抗赘生剂且特异性结合人IGF-IR和人ErbB3的新颖单特异性和双特异性抗体。示例性抗体抑制经由IGF-IR和ErbB3中的任一者或两者进行的信号转导。示例性多价蛋白质包含至少一个抗IGF-1R结合位点和至少一个抗ErbB3结合位点。在某些实施方案中，结合位点可经由免疫球蛋白恒定区连接。还提供新颖抗ErbB3和抗IGF-1R抗体(例如，单克隆抗体)。

Drugs covered by this patent

Patent Metadata

Patent number
CN105884900A
Jurisdiction
CN
Classification
—
Expires
2016-08-24
Drug substance claim
No
Drug product claim
No
Assignee
Merrimack Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.